UPDATE: UBS Investment Research Lowers PT on CME Group Following Solid 2Q Results
In a report published Friday, UBS Investment Research analyst Alex Kramm reiterated a Buy rating on CME Group (NASDAQ: CME), but lowered the price target from $84.00 to $83.00.
In the report, UBS Investment Research noted, “Despite solid 2Q results CME declined some 3% today. We believe investors were overly focused on slightly higher expense guidance, lower OTC clearing fee capture, energy pricing incentives, and a sharp slowdown in July volumes (from elevated levels). Given the significant run in the shares in May/June, we are not surprised to see the stock take some pause. That said, we believe the current weakness provides a nice set-up into the fall, when debate about monetary policy should increase again and new growth initiatives play out further.”
CME Group closed on Thursday at $72.17.
Latest Ratings for CME
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Rosenblatt | Maintains | Neutral | |
Mar 2022 | UBS | Maintains | Buy | |
Mar 2022 | Credit Suisse | Maintains | Neutral |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Alex Kramm UBS Investment ResearchAnalyst Color Price Target Analyst Ratings